News Coverage 10.20.20 Share on Twitter Share on Facebook Share on LinkedIn The international neoantigen initiative Tumour Neoantigen Selection Alliance (TESLA) has identified key parameters for immunotherapy advancement. Related Announcement, Press Release Parker Institute Commits Additional $125M for Audacious Mission to Cure Cancer Announcement, Press Release The Parker Institute for Cancer Immunotherapy Awards More Than $1 Million to Four Early Career Investigators Announcement Behind the Breakthrough: An Interview with Carl June, the Father of CAR T-Cell Therapy
Announcement, Press Release Parker Institute Commits Additional $125M for Audacious Mission to Cure Cancer
Announcement, Press Release The Parker Institute for Cancer Immunotherapy Awards More Than $1 Million to Four Early Career Investigators